Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

27

Revenue 2017

Gilenya

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gilenya was produced by Novartis.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Mayzent is a follow-up to Novartis’ blockbuster MS therapy Gilenya (fingolimod), which brought in $2.5bn in the first nine months of the year and is facing the threat of

Novartis files for approval of MS drug in EU, US

Novartis files for approval of MS drug in EU, US Siponimod (BAF312) – which is a follow-up to Novartis’ established MS therapy Gilenya (fingolimod) – is the first and so far only drug to have demonstrated it can delay the progression of ... That’s the same mechanism as $3bn-a-year product

Dismay as NICE rejects Roche’s MS drug Ocrevus

Dismay as NICE rejects Roche’s MS drug Ocrevus such as Novartis’ Gilenya (fingolimod) and Biogen’s Tecfidera (dimethyl fumarate).

Novartis buys gene therapy firm AveXis for $8.7bn

Novartis buys gene therapy firm AveXis for $8.7bn some big sellers like cancer drug Afinitor and Gilenya for multiple sclerosis in 2019, according to a report on aktiencheck.de.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug So far there is just one S1P modulator - Novartis’ Gilenya (fingolimod) - on the market. ... Gilenya has some off-target effects, such as slowing of the heart that requires monitoring on first dosing, and has been linked to liver function abnormalities.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics